Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lotus Pharmaceutical CoTPE:1795 -0.83%74 Earnings Yield (Joel Greenblatt) % is 8.44% as of Jun. 2026, which is 44% above its 10-year median of 5.87. GuruFocus rates TPE:1795 with a GF Score™ of 74/100 and a GF Value™ of NT$464.14 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,010 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks better than 77.52% on this metric.
Lotus Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$93,803 Mil.
Lotus Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$7,914 Mil. Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 8.44%.
The historical rank and industry rank for Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
TPE:1795'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.49 Med: 5.87 Max: 11.7
Current: 8.69
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Lotus Pharmaceutical Co was 11.70%. The lowest was 0.49%. And the median was 5.87%.
TPE:1795's Earnings Yield (Joel Greenblatt) % is ranked better than 77.52% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 2.92
vs TPE:1795: 8.69
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Lotus Pharmaceutical Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 21.41%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Lotus Pharmaceutical Co (TPE:1795) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Lotus Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Related Terms
Lotus Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Chart
TPE:1795 vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % falls into.
Lotus Pharmaceutical Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Lotus Pharmaceutical Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Lotus Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7,914 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 8.44% mean?
Lotus Pharmaceutical Co (TPE:1795) has a Earnings Yield (Joel Greenblatt) % of 8.44% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Lotus Pharmaceutical Co and its competitors. This is 44% above median its historical median of 5.87. Over the past decade, Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % has ranged from 0.49 to 11.70. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #227 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 22.5%.
Is Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % too high?
Lotus Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 8.44% is 44% above median its 10-year median of 5.87. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 11.70. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 2.92. Lotus Pharmaceutical Co's value of 8.44% is 189% above this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #227 out of 1010 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lotus Pharmaceutical Co has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #227 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This places Lotus Pharmaceutical Co in the top 23% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 2.92. Lotus Pharmaceutical Co's value of 8.44% is 189% above this benchmark. Historically, Lotus Pharmaceutical Co's own Earnings Yield (Joel Greenblatt) % has ranged from 0.49 to 11.70 over the past decade. While the company's 10-year median is 5.87 vs. the industry median of 2.92, Lotus Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 2.92, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % of 8.44% is 189% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current Earnings Yield (Joel Greenblatt) % is 8.44%, which is 44% above median its own 10-year median of 5.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$464.14, compared to a current price of NT$179.00 — trading 61.4% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 8.44%, which is 44% above median its 10-year median of 5.87 and 189% above the Drug Manufacturers industry median of 2.92. Lotus Pharmaceutical Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current Earnings Yield (Joel Greenblatt) % is 8.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$179.00 is trading 61.4% below its estimated GF Value™ of NT$464.14.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
Earnings Yield (Joel Greenblatt) %: 8.44% (44% above median its 10-year median of 5.87)
GF Value™: NT$464.14 vs. price of NT$179.00 (61.4% below fair value)
Industry Position: 189% above the Drug Manufacturers median (#227 of 1010)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
74GF Score
Get the complete analysis for TPE:1795
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
